Four week therapy with Transition Therapeutics' E1-I.N.T.(TM) leads to sustained reduction in blood glucose levels

---

Transition Therapeutics Inc. announces the results from its exploratory Phase IIa clinical trial indicating that four weeks of daily treatments with gastrin-based therapy, E1-I.N.T.(TM), showed sustained reductions in blood glucose control parameters, including haemoglobinA1C (HbA1c), for 6 months post-treatment. The type 2 diabetes patients enrolled in this study were using metformin with/without thiazolidinediones (TZD).

"These data are very encouraging and show the potential of a regenerative therapy in diabetes," said Sherwyn Schwartz, MD, a noted diabetes researcher and the director of the Diabetes & Glandular Disease Research Associates in San Antonio, TX who was the lead investigator of the study.

"Achieving sustained improvements in glucose control for many months post-treatment following a four week therapy is unprecedented in type 2 diabetes. The improvements in HbA1c correlated with changes in multiple other clinical parameters suggesting that gastrin-based therapies, and specifically E1-I.N.T.(TM), have the potential to re-engage the body's natural mechanism to regulate glucose," said Dr. Tony Cruz, chairman and chief executive officer of Transition. "The immediate goal is to optimize the dosing regimen in a larger phase II study."